PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
176.45 - 178.59
86.62 - 184.48
124.91M / 173.95M (Avg.)
50.81 | 3.50
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
17.04%
Revenue growth above 1.5x AVGO's 6.32%. David Dodd would confirm if the firm has a unique advantage driving sales higher.
11.76%
Gross profit growth above 1.5x AVGO's 4.96%. David Dodd would confirm if the company's business model is superior in terms of production costs or pricing.
13.92%
Positive EBIT growth while AVGO is negative. John Neff might see a substantial edge in operational management.
13.92%
Operating income growth above 1.5x AVGO's 1.00%. David Dodd would confirm if consistent cost or pricing advantages drive this outperformance.
14.32%
Positive net income growth while AVGO is negative. John Neff might see a big relative performance advantage.
27.78%
Positive EPS growth while AVGO is negative. John Neff might see a significant comparative advantage in per-share earnings dynamics.
8.33%
Positive diluted EPS growth while AVGO is negative. John Neff might view this as a strong relative advantage in controlling dilution.
-14.98%
Share reduction while AVGO is at 0.15%. Joel Greenblatt would see if the company has a better buyback policy than the competitor.
3.01%
Diluted share count expanding well above AVGO's 0.70%. Michael Burry would fear significant dilution to existing owners' stakes.
No Data
No Data available this quarter, please select a different quarter.
2.58%
OCF growth under 50% of AVGO's 9.32%. Michael Burry might suspect questionable revenue recognition or rising costs.
175.14%
FCF growth above 1.5x AVGO's 9.56%. David Dodd would verify if the firm’s strategic investments yield superior returns.
537.74%
10Y revenue/share CAGR 1.25-1.5x AVGO's 416.86%. Bruce Berkowitz would investigate brand strength or geographical expansion fueling growth.
537.74%
5Y revenue/share CAGR above 1.5x AVGO's 134.28%. David Dodd would look for consistent product or market expansions fueling outperformance.
537.74%
3Y revenue/share CAGR above 1.5x AVGO's 62.33%. David Dodd would confirm if there's an emerging competitive moat driving recent gains.
1014.35%
10Y OCF/share CAGR above 1.5x AVGO's 580.47%. David Dodd would check if a superior product mix or cost edge drives this outperformance.
1014.35%
5Y OCF/share CAGR above 1.5x AVGO's 92.77%. David Dodd would confirm if the firm has better cost structures or brand premium boosting mid-term cash flow.
1014.35%
3Y OCF/share CAGR above 1.5x AVGO's 39.51%. David Dodd would confirm if the firm is quickly gaining an operational edge over the competitor.
926.41%
Similar net income/share CAGR to AVGO's 869.72%. Walter Schloss would see parallel tailwinds or expansions for both firms.
926.41%
5Y net income/share CAGR above 1.5x AVGO's 414.43%. David Dodd would confirm if the firm’s strategy is more effective in generating mid-term profits.
926.41%
3Y net income/share CAGR above 1.5x AVGO's 16.00%. David Dodd would confirm the company’s short-term strategies outmatch the competitor significantly.
779.74%
10Y equity/share CAGR in line with AVGO's 862.23%. Walter Schloss might see both benefiting from stable profitability and moderate payout ratios over the decade.
779.74%
5Y equity/share CAGR above 1.5x AVGO's 165.61%. David Dodd might see stronger earnings retention or fewer asset impairments fueling growth.
779.74%
3Y equity/share CAGR above 1.5x AVGO's 201.93%. David Dodd verifies the company’s short-term capital management far exceeds the competitor’s pace.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
2.77%
Our AR growth while AVGO is cutting. John Neff questions if the competitor outperforms in collections or if we’re pushing credit to maintain sales.
18.73%
Inventory growth well above AVGO's 8.08%. Michael Burry suspects overshooting production or weaker sell-through vs. the competitor.
6.42%
Asset growth above 1.5x AVGO's 0.60%. David Dodd checks if M&A or new capacity expansions are value-accretive vs. competitor's approach.
33.76%
BV/share growth above 1.5x AVGO's 5.15%. David Dodd confirms if consistent profit retention or fewer write-downs yield faster equity creation.
-0.28%
Both reduce debt yoy. Martin Whitman sees a broader sector shift to safer balance sheets or less growth impetus.
17.89%
R&D growth drastically higher vs. AVGO's 13.26%. Michael Burry fears near-term margin erosion unless breakthroughs are imminent.
10.81%
We expand SG&A while AVGO cuts. John Neff might see the competitor as more cost-optimized unless we expect big payoffs from the overhead growth.